FDA-approved first-line medicines for metastatic NSCLC patients whose tumors possess EGFR exon 21 L858R mutations or EGFR exon 19 deletions are gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.